Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 39.0 | 51 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 50.0 | 62 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 41.0 | 63 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 39.5 | 64 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 26.0 | 65 | |
RA2159 | PI103 | 0.1 | uM | 1 | IFN-a2 | 21.0 | 67 | ||||
N2586 | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 109.0 | 49 | ||||
N2586 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 115.5 | 58 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 171.0 | 53 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 125.0 | 73 | |
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 115.5 | 56 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | IFN-a2 | 59.0 | 40 | |
N2586 | PI103 | 0.1 | uM | 1 | IFN-a2 | 35.0 | 57 | ||||
RA2159 | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 22.0 | 69 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 20.0 | 78 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 17.0 | 59 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 20.0 | 52 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 24.0 | 64 | |
RA2159 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 21.0 | 61 | |
RA2159 | Sigma A6730 | 3.0 | uM | 1 | IFN-a2 | 22.0 | 61 | ||||
N2586 | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 51.0 | 53 | ||||
N2586 | PD184352 | 0.1 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 45.5 | 56 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 39.0 | 49 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 44.0 | 33 | |
N2586 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 1 | IFN-a2 | 42.0 | 43 |